Novo Nordisk A/S: Phase 2 study closed enrollment, 233 enrolled (Obesity)
Novo Nordisk A/S: Phase 2 study closed enrollment, 233 enrolled (Obesity). Its enrollment of 233 is above the median of 80 (79th percentile). Dated 50 days ago, it serves as a historical benchmark. Score 75/100. As of 2026-11-05, from ClinicalTrials.gov (U.S. National Library of Medicine) API v2.
Data as of · Compiled by Zalwin from ClinicalTrials.gov (U.S. National Library of Medicine) API v2
enrollment: 233 · 79th percentile of 9,177 ClinicalTrialStartPulse records · 2.9x the median
Free preview: all 15 published fields of this record are shown below. Locked: 499 related US ClinicalTrialStartPulse records and the 7-column CSV export.
| Field | Value |
|---|---|
| Sponsor | Novo Nordisk A/S |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity |
| NCT ID | NCT07639021 |
| Phase | Phase 2 |
| Status | active not recruiting |
| Conditions | Obesity |
| Intervention types | drug |
| Target enrollment | 233 |
| Site countries | United States, Puerto Rico |
| Posted | 2026-06-10 |
| Planned start | 2026-06-09 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-09-16 |
| Last update posted | 2026-09-16 |
| enrollment percentile | 79th of 9,177 (median 80, 2.9x median) |
| Peer records CSV (500 US records) | 🔒 Click to unlock → |
| CRM-ready export with official source URLs | 🔒 Click to unlock → |
Watch Novo Nordisk A/S
Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.
Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.
Unlock Novo Nordisk A/S + 500 US peer records (CSV)
Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Sponsor · Phase · Conditions · Enrollment · Countries · Event · Posted · official source URL
- Source agency: ClinicalTrials.gov (U.S. National Library of Medicine) API v2
- Record date: 2026-09-16
- Data refreshed: 2026-11-05
- Refunds on request within 14 days
Top ClinicalTrialStartPulse records (US first): Sanofi · Pfizer · National Institute of Arthritis and Musculoskeletal and Skin · Apple Inc. · National Institutes of Health Clinical Center (CC) · Browse all by state and category →
LIVE PUBLIC DATA Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 · Last refreshed: Thu, 05 Nov 2026 08:46:16 GMT
Is this your business? Add a "Listed on Zalwin" badge to your site
Paste this snippet into your website. It links to this public record; nothing is tracked on your site.
Peer benchmark and outreach value: Novo Nordisk A/S and 2,595 US peers
- US ClinicalTrialStartPulse records like this one: 2,595
- Novo Nordisk A/S's enrollment: 79th percentile of 9,177 records
- Timing: Low: older than 30 days
- Estimated pipeline if you contact every US peer: $519,000 (peers × rate × deal size; an estimate from your assumptions, not a forecast)
75 / 100 Score
- Industry sponsor (buys outsourced services).
- Enrollment closed: data management, monitoring and closeout ahead.
- Phase 2: multi-site, larger budget.
- 233 participants planned.
What is the ClinicalTrialStartPulse record for Novo Nordisk A/S?
Novo Nordisk A/S's Phase 2 study (NCT07639021) in Obesity, first posted 2026-06-10: enrollment closed (active, not recruiting) (2026-09-16), in an update posted 2026-09-16.
How does Novo Nordisk A/S compare to other ClinicalTrialStartPulse records?
Its enrollment of 233 sits in the upper half (79th percentile) of 9,177 records; the median is 80. It is 50 days old; check the official source for later updates before acting. Its Score of 75/100 puts it among the stronger signals in this feed.
Novo Nordisk A/S vs. top 3 peers
| Organization | Location | Amount | Percentile | Record date |
|---|---|---|---|---|
| Novo Nordisk A/S | US | 233 | 79th | 2026-09-16 |
| argenx | US | 229 | 79th | 2026-11-04 |
| Genmab | US | 194 | 75th | 2026-11-04 |
| Xilio Development, Inc. | US | 180 | 74th | 2026-11-04 |
Related records
ClinicalTrialStartPulse: Phase 2 ClinicalTrialStartPulse: United States sites
More US public-record feeds
U.S. DOT Injury/Illness Summary Pulse in US U.S. DOT FRA Regulated Mode Major Security Events Pulse in US U.S. DOT Crossing Inventory Data Pulse in US U.S. DOT Insur - All With History Pulse in US USAC Telecom CAF Locations Obligation and Deployment by Speed Tier Data Pul in US U.S. CDC 2022 Final Assisted Reproductive Technology Summary Pulse in US U.S. DOT Rail Equipment Accident/Incident Data Subset Pulse in US U.S. DOT Monthly Modal Time Series Pulse in US
How to monitor Novo Nordisk A/S and peer phase 2 records
Get new ClinicalTrialStartPulse records like Novo Nordisk A/S by email (free, weekly)
We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.
Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.
Get new studies in your therapeutic areas
ClinicalTrialStartPulse emails new studies and status changes matching your events, phases, sponsor types and site regions.
✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.